Opus Genetics Hosts Inaugural Patient Advocacy Outreach Webinar on Inherited Retinal Diseases
01 sept. 2022 08h28 HE
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the release...
Opus Genetics Expands its Leadership Team
21 juil. 2022 08h00 HE
|
Opus Genetics
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-Clinical Development Erin O’Neil, M.D., appointed Vice President of Clinical Development Sarah Tuller, J.D., RAC, appointed Vice...
Opus Genetics to Present at OIS Retina Innovation Summit 2022
11 juil. 2022 07h30 HE
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Ben...
Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
21 juin 2022 07h30 HE
|
Opus Genetics
Industry veteran and experienced CEO will continue to lead the company as its AAV-based gene therapies for inherited retinal diseases approach the clinic RESEARCH TRIANGLE PARK, N.C., June 21, 2022 ...
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
11 mai 2022 08h00 HE
|
Opus Genetics
RESEARCH TRIANGLE PARK, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced the...
Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
04 mai 2022 16h05 HE
|
Opus Genetics
Retinal regions of preserved photoreceptors identified as targets for subretinal delivery of AAV8-based gene therapy to address mutations in genes that cause forms of Leber congenital amaurosis ...
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
28 avr. 2022 08h00 HE
|
Opus Genetics
RALEIGH, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced that data from two...
Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseases
11 avr. 2022 08h00 HE
|
Opus Genetics
RALEIGH, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for inherited retinal diseases, today announced a strategic...
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
15 févr. 2022 07h30 HE
|
Opus Genetics
RALEIGH, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced the appointment of...
Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease
11 nov. 2021 10h36 HE
|
Opus Genetics
RALEIGH, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-focused gene therapy company developing treatments for orphan inherited retinal diseases, today announced an agreement to...